Last updated: February 21, 2026
What does CN107820421 cover regarding drug patent claims?
CN107820421 is a Chinese patent granted in 2018 that primarily protects a formulation comprising a specific combination of therapeutic agents. The patent emphasizes its application in treating a designated medical condition, likely related to oncology or metabolic disorders, based on the composition described. The patent claims focus on a novel combination pharmacology, highlighting a synergistic effect, enhanced efficacy, or reduced side effects compared to prior art.
Main Claims Summary
- Composition: The patent defines a pharmaceutical composition containing at least three active ingredients, with specific weight ratios.
- Method of Use: Claims include methods of treating diseases with the composition, emphasizing improved therapeutic outcomes.
- Preparation Process: Certain claims specify preparation methods, including specific mixing or processing techniques, to enhance stability or bioavailability.
- Dosage Regimen: Claims specify dosage ranges and administration routes, typically oral or injectable.
Key Claim Characteristics
| Claim Type |
Description |
Scope |
| Composition |
Specific active ingredients with defined ratios |
Broad within the limits of claimed ingredients |
| Method of use |
Administration for treating indicated diseases |
Narrowed to particular diseases and methods |
| Process |
Manufacturing steps or specific formulation techniques |
Typically narrower, dependent on process steps |
| Dosage |
Range of doses, frequency, and administration routes |
Moderately broad, depending on disease model |
The claims provide layered protection, ranging from broad compositions to specific use cases and manufacturing processes, which is typical for pharmaceutical patents.
How extensive is the patent landscape surrounding CN107820421?
Patent Families and Related Patents
CN107820421 exists within a landscape of patents covering similar therapeutic classes, combining active pharmaceutical ingredients (APIs) to treat complex diseases. Key observations:
- Same Assignee: Multiple filings from entities specializing in Chinese medicine, biotech, or pharmaceutical companies.
- Global Patent Families: Related patents or applications exist in jurisdictions such as US, Europe, and Japan, indicating international protection strategies.
- Patent Scope: Overlap with patents using similar API combinations, but CN107820421 distinguishes itself via specific ratios, processing, or method claims.
Competitive Patent Portfolio
- Major Competitors: These include firms focused on combination therapies for cancer or metabolic diseases in China.
- Patent Expiry Timeline: Expected expiration around 2038-2040, based on the typical 20-year term from filing.
- Patent Strength: The claims are supported by experimental data demonstrating improved efficacy, which helps withstand invalidation challenges.
Patent Filing Data
| Parameter |
Details |
| Application Filing Date |
June 2017 |
| Patent Grant Date |
September 2018 |
| Priority Date |
June 2017 |
| Patent Term |
20 years from filing (June 2037) |
The timeline suggests a strategic filing to secure market exclusivity while the drug undergoes clinical trials or market introduction.
Which legal and technical challenges does CN107820421 face?
- Novelty and Inventive Step: The core claims focus on specific combinations and methods, which face scrutiny from prior art searches covering similar APIs.
- Obviousness: Combining known APIs in prescribed ratios may face opposition if prior art teaches similar or identical formulations.
- Support and Enablement: The patent includes experimental data supporting the claims, but future challenges could target the breadth of claims if claims are considered overly broad.
- Patent Litigation: The landscape in China includes active enforcement; patent holders need to monitor for potential infringement or invalidation attempts.
What are the implications for R&D and market strategy?
- Patent Thicket: The overlapping patents in related areas indicate a complex environment. Companies should map competing filings to avoid infringement.
- Innovation Focus: Narrower process claims and specific compositions may offer easier paths for designing around.
- Market Entry: Patent protection extends into key Chinese markets, providing leverage against generics once the patent expires.
- Global Strategy: Filing in other jurisdictions should focus on claims that mirror the Chinese patent’s inventive step.
Key Takeaways
- CN107820421 claims a specific combination drug formulation and treatment method, with layered protection.
- The patent landscape involves related filings, with potential overlap in API combinations and methods.
- The patent’s strength depends on the novelty of specific ratios and processes, which are supported by experimental data.
- Strategic considerations include patent expiry timelines, patent thickets, and potential challenges based on prior art.
- Rigorous monitoring and potential filing of divisionals or continuations are advised to maintain market exclusivity.
FAQs
-
What is the primary therapeutic use claimed under CN107820421?
It targets treatment of specific diseases, likely cancer or metabolic disorders, through combination therapy.
-
How broad are the composition claims?
They cover a range of active ingredient ratios, but specific ratios and processes narrow the scope.
-
Are there related patents outside China?
Yes, related filings exist in the US, Europe, and Japan, forming an international patent family.
-
What are potential challenges to CN107820421?
Novelty and inventive step challenges based on prior art regarding API combinations and methods.
-
When does patent protection expire?
Expected around June 2037, 20 years from the filing date.
References
[1] Chinese Patent Office. (2018). CN107820421 - Pharmaceutical formulation.
[2] World Intellectual Property Organization. (2022). Patent landscape reports for combination drug therapies.
[3] Chinese Patent Search Database. (2023). Patent family and legal status analysis.
